Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · IEX Real-Time Price · USD
11.41
+0.58 (5.36%)
At close: Jul 2, 2024, 4:00 PM
11.70
+0.29 (2.54%)
After-hours: Jul 2, 2024, 4:36 PM EDT
Pulse Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
56
Market Cap
630.12M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 700.00K | -718.00K | -50.63% |
Dec 31, 2021 | 1.42M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.00B |
Clover Health Investments | 1.85B |
Definitive Healthcare | 255.69M |
Travere Therapeutics | 183.23M |
Weave Communications | 178.08M |
Wave Life Sciences | 112.91M |
Lexicon Pharmaceuticals | 2.31M |
PLSE News
- 4 days ago - Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering - Business Wire
- 4 weeks ago - Pulse Biosciences, Inc. Announces Commencement of Rights Offering - Business Wire
- 6 weeks ago - Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 - Business Wire
- 6 weeks ago - Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting - Business Wire
- 7 weeks ago - Pulse Biosciences Enhances Executive Leadership Team - Business Wire
- 7 weeks ago - Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System - Business Wire
- 2 months ago - Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results - Business Wire
- 2 months ago - Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 - Business Wire